Journal
PHARMACOLOGY & THERAPEUTICS
Volume 131, Issue 2, Pages 179-186Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2011.02.005
Keywords
Interleukin; Cardiovascular; Inflammation; Atherosclerosis; Obesity; Diabetes
Categories
Funding
- BHF [FS/08/035/25309]
- British Heart Foundation [FS/08/035/25309] Funding Source: researchfish
- Medical Research Council [G9818261, G0801198] Funding Source: researchfish
- MRC [G0801198, G9818261] Funding Source: UKRI
Ask authors/readers for more resources
Numerous pro-inflammatory cytokines have been implicated in the pathogenesis of several cardiovascular diseases. Interleukin (IL)-33 is a new member of the IL-1 family of cytokines that promotes Th2 type immune responses by signaling through the ST2L and IL-1RAcP dimeric receptor complex. Furthermore, the biological effects of IL-33 are limited by a soluble decoy form of ST2 (sST2). Recent studies indicate a protective role for IL-33 and ST2L in atherosclerosis, obesity and cardiac remodeling. The present review summarizes currently available data showing the role for IL-33 and its receptor ST2L within cardiovascular disease, and the potential use of sST2 as a predictive cardiovascular biomarker. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
